Abstract:Journal of Oncology Pharmacy Practice, Ahead of Print. IntroductionAbiraterone is a standard treatment for prostate cancer and is a preferred treatment option at the Veterans Affairs North Texas Health Care System (VANTXHCS) due to its formulation, cost, and overall tolerability. In the combined data of five randomized controlled trials, grade 3 and 4 liver enzyme increases were reported in 6% of patients, most commonly within the first three months of initiating abiraterone. Therefore, the prescribing information recommends measuring serum transaminases and bilirubin levels (liver function tests, LFTs) every two weeks for the first three months of treatment and monthly thereafter. VANTXHCS utilizes a modified monitoring approach in which LFTs are evaluated two weeks after initiating abiraterone and less frequently thereafter. The purpose of this study is to assess if the modified monitoring approach leads to an increase in incidence and/or severity of abiraterone-induced hepatotoxicity.MethodsA retrospective analysis was conducted within the VANTXHCS electronic record system to include adult patients diagnosed with prostate cancer who initiated abiraterone between January 1, 2014 and December 31, 2022. Patients were excluded if they were enrolled in clinical trials or were receiving care from an outside provider due to lack of accessible laboratory data. The primary outcome was to assess the incidence and severity of LFT elevations up to six months after initiation. Select secondary outcomes include time to LFT elevation, management of LFT elevation, and incidence and severity of LFT elevation up to 12 months after initiation.ResultsA total of 274 patients were included in the analysis, of which 72 (26.3%) experienced any grade LFT elevations during the 6-month period. Of those with LFT elevations, grade 1 elevations occurred in 48 (17.5%) patients, grade 2 in 20 (7.3%) patients, grade 3 in 3 (1.1%) patients, and grade 4 in 1 (0.4%) patient. The median time to detecting LFT elevations was 8 (4–16) weeks. The median time to resolution was 4 (3–7) weeks. Seventy-five percent of the patients with LFT elevations within 6 months of therapy were monitored without any interruptions in abiraterone therapy.ConclusionThe current findings suggest that the modified monitoring approach to abiraterone does not result in an increase in incidence and/or severity of hepatotoxicity compared to the previously published clinical trial data. The modified monitoring approach may have a beneficial impact on healthcare resources.

Hospitalization for adverse events under abiraterone or enzalutamide exposure in real‐world setting: A French population‐based study on prostate cancer patients

Mp48-19 Risk Of Metabolic And Cardiovascular Adverse Events With Abiraterone Or Enzalutamide Among Men With Advanced Prostate Cancer

Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide

Hospitalizations among veterans treated for metastatic prostate cancer with abiraterone or enzalutamide

The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based study

Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer

Real-world treatment patterns among French patients with metastatic castration-resistant prostate cancer under abiraterone or enzalutamide.

Clinical outcomes in metastatic prostate adenocarcinoma treated with abiraterone and enzalutamide

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review

Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China

Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience

Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer

Comparison of pneumonia and sepsis risks between enzalutamide and abiraterone in patients with prostate cancer

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials

Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS)

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer

Modified monitoring of abiraterone acetate-induced hepatotoxicity in prostate cancer patients

Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study

Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study